Background
Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide, with a constantly increasing frequency, especially in China [
1]. Despite recent advances in clinical and experimental oncology, the long-term prognosis of HCC patients remains poor, due to late detection of disease, frequent cancer metastasis, high recurrence rate, and lack of effective therapeutic intervention for terminally staged tumors. Previous studies have revealed many HCC-associated deregulated genes and signaling pathways [
2,
3], but the highly complex molecular mechanisms underlying its carcinogenesis and progression are still obscure. Therefore, it is urgent to identify reliable biomarkers of HCC for its early diagnosis, effective therapy, and prognosis evaluation.
Long noncoding RNA (lncRNA), >200 nucleotides in length, is a type of noncoding RNA molecule that can regulate gene expression in transcriptional or posttranscriptional level [
4,
5]. Recent research has shown that lncRNAs participate in a large number of cellular processes, such as cell proliferation, differentiation, apoptosis, and cell cycle progression [
6]. Emerging evidence indicates that lncRNAs play important roles in the biology of human cancers, which may provide a new but promising way to deal with cancer [
7]. Functional lncRNAs may be applied for cancer diagnosis and prognosis and also act as potential novel therapeutic targets. For example, increased expression of lncRNA HOTTIP enhances tumor growth and migration in pancreatic cancer [
8]. LncRNA MALAT1 overexpression is a negative prognostic factor for lung cancer [
9]. LincRNAs VLDLR, PVT1, and GAS5 could regulate tumor cell responses to chemotherapy [
10‐
12]. However, the understanding of the expression and function of lncRNAs in HCC is still in the early stage.
BRAF-activated noncoding RNA (BANCR), a 693-bp lncRNA, was originally identified in melanoma cells by Flockhart RJ et al. [
13]. Subsequently, aberrant lncRNA BANCR expression has been confirmed in papillary thyroid carcinoma [
14], retinoblastoma [
15], lung cancer [
16,
17], gastric cancer [
18], and colorectal cancer [
19]. In these tumors, BANCR regulated cell proliferation, migration, and invasion and may serve as a potential oncogene or a candidate tumor suppressor. However, no report of BANCR in HCC has been found. In the present study, we examined BANCR expression in HCC tissues and cell lines. We also investigated the correlation between BANCR levels and clinicopathological characteristics and patient’s survival. Moreover, we explored the role of BANCR in the regulation of biological behaviors of HCC cells.
Methods
Patients and clinical specimens
This study was approved by the Research Ethics Committee of Qi-Lu Hospital. Written informed consent was obtained from all of the patients. All specimens were handled and made anonymous according to the ethical and legal standards.
Matched fresh specimens of HCC and adjacent noncancerous liver tissues were obtained from 109 patients who underwent hepatic resection at Qi-Lu Hospital between January 2008 and March 2010. All tissues were immediately frozen in liquid nitrogen and stored at −80 °C until analysis. None of the patients had undergone chemotherapy or radiotherapy before surgery. Details of clinical and pathological characteristics of the patients are summarized in Table
1. Follow-up data were available for all patients. Overall survival was defined as the amount of time from the day of primary surgery to the date of death or the end of follow-up (for living patients).
Table 1
Correlation between BANCR expression and different clinicopathological features in patients with hepatocellular carcinoma
Age |
<60 | 53 | 29 (54.7 %) | 24 (45.3 %) | 0.845 |
≥60 | 56 | 26 (46.4 %) | 30 (53.6 %) | |
Gender |
Male | 80 | 39 (48.8 %) | 41 (51.2 %) | 0.666 |
Female | 29 | 16 (55.2 %) | 13 (44.8 %) | |
Tumor grade |
G1 | 34 | 24 (70.6 %) | 10 (29.4 %) | 0.007 |
G2 + G3 | 75 | 31 (41.3 %) | 44 (58.7 %) | |
AFP (ng/L) |
≥400 | 61 | 27 (44.4 %) | 34 (55.6 %) | 0.178 |
<400 | 48 | 28 (58.3 %) | 20 (41.7 %) | |
With cirrhosis |
Yes | 74 | 36 (48.6 %) | 38 (51.4 %) | 0.683 |
No | 35 | 19 (54.3 %) | 16 (45.7 %) | |
Tumor diameter (cm) |
<5 | 66 | 41 (62.1 %) | 25 (37.9 %) | 0.003 |
≥5 | 43 | 14 (32.6 %) | 29 (67.4 %) | |
Tumor nodes |
Multi | 37 | 15 (40.5 %) | 22 (59.5 %) | 0.16 |
Single | 72 | 40 (55.6 %) | 32 (44.4 %) | |
Venous infiltration |
Presence | 39 | 11 (28.2 %) | 28 (71.8 %) | 0.001 |
Absence | 70 | 44 (62.9 %) | 26 (37.1 %) | |
TNM stage |
I + II | 51 | 34 (66.7 %) | 17 (33.3 %) | 0.002 |
III | 58 | 21 (36.2 %) | 37 (66.8 %) | |
Cell culture and RNA interference
Human HCC cell lines (HuH-7, Hep3B, HepG2, and H2-M) and human normal hepatocyte CL-48 were obtained from the Institute of Biochemistry and Cell Biology of the Chinese Academy of Sciences (Shanghai, China). The cells were maintained in high glucose (4.5 g/l) Dulbecco’s modified Eagle’s medium (DMEM; Gibco-BRL, Gaithersburg, MD) supplemented with 10 % heat-inactivated fetal bovine serum (FBS), 100 U/ml of penicillin and 100 μg/ml streptomycin sulfate. Cultures were incubated in a humidified atmosphere of 5 % CO2 at 37 °C.
lncRNA BANCR small interfering RNA (si-BANCR) and nontargeting small interfering RNA (siRNA) (si-NC) were purchased from Sigma-Aldrich. HCC cells were transfected with siRNA by using Lipofectamine 2000 (Invitrogen, CA, USA) according to the manufacturer’s instructions. The cells were harvested for further assays 48 h after transfection.
Total RNA was extracted using the Trizol reagent (Invitrogen, Carlsbad, CA) according to the manufacturer’s instructions. RNA was reverse transcribed into cDNA using the Prime-Script one step RT-PCR kit (Takara, Dalian, China). BANCR expression levels were measured with quantitative real-time PCR (qRT-PCR) using an ABI7500 system and the SYBR Green PCR Master Mix (Takara). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal control. The primer sequences for BANCR were 5′-ACAGGACTCCATGGCAAACG-3′ (forward) and 5′-ATGAAGAAAGCCTGGTGCAGT-3′ (reverse). Each assay was performed in triplicate, and relative BANCR expression was normalized to GAPDH using the 2−ΔCt method.
Cell proliferation assay
Cell proliferation was analyzed using MTT assay. Briefly, approximately 1 × 103 cells were seeded into a 96-well plate and incubated for 1, 2, 3, and 4 days. At the indicated time point, 20 μl of MTT (5 mg/ml) (Sigma, USA) was added into each well and incubated for another 4 h. Then, the supernatants were removed, and 150 μl of DMSO (Sigma, USA) was added to terminate the reaction. The absorbance value (OD) was measured at 490 nm on a microplate reader (Molecular Devices, Sunnyvale, CA, USA).
Detection of apoptosis by flow cytometry
Forty-eight hours after transfection, the HCC cells were harvested, washed, and resuspended in ice-cold PBS. The cells were then treated with propidium iodide (10 μg/ml; Sigma) and Annexin V-FITC (50 μg/ml, BD) in the dark for 15 min at room temperature and examined by flow cytometry (FACScan; BD Biosciences).
Cell invasion and migration assays
Six-well transwell chambers (8-μm pore size, Corning, New York, USA) were used to investigate cell invasion and migration. For migration assay, about 1 × 105 HCC cells in serum-free media were seeded into the upper chambers after siRNA transfection. The lower chamber contained medium with 20 % FBS to stimulate migration. Following a 48 h-incubation, the cells located on the lower surface of the chamber were fixed with 95 % ethanol for 10 min, stained with 0.1 % crystal violet for 20 min, and counted using a microscope (Olympus Corp., Tokyo, Japan). For invasion assay, the upper chambers were first covered with 5 mg/ml Matrigel, and the other steps were the same as migration.
Western blot
Cells were lysed in RIPA buffer with protease inhibitors and phosphatase inhibitors. The protein extracts were loaded onto a 10 % sodium SDS-PAGE gel and transferred to a PVDF membrane. The blots were probed with primary antibodies (Cell signal technology, USA) followed by the HRP-conjugated secondary antibody. Following three Tris-buffered saline containing 0.1 % Tween-20 (TBST) washes, the membranes were developed using ECL Plus (Millipore, MA, USA) and exposed to X-ray film. GAPDH served as the loading control.
Statistics
All statistical analyses were performed using the SPSS 16.0 software package (SPSS, Chicago, IL, USA). The significance of differences between groups was estimated by Student’s t test and chi-square test. Survival curves were constructed with the Kaplan–Meier method and compared by the log-rank test. The significance of survival variables was evaluated using a multivariate Cox proportional hazards regression analysis. P < 0.05 was considered statistically significant.
Discussion
Identifying novel molecules that take part in HCC formation and progression may be helpful for improving the diagnosis, prevention, and treatment of this disease. The relationship between lncRNAs and tumors has currently become one of the focuses of cancer studies. Abnormal expression of several lncRNAs has been reported in HCC. For example, lncRNA AOC4P overexpression in HCC cells significantly reduced cell proliferation, migration, and invasion by inhibiting the epithelial-mesenchymal transition (EMT) [
20]. lncRNA UCA1 was aberrantly upregulated in HCC tissues and associated with TNM stage, metastasis, and postoperative survival [
21]. UCA1 depletion inhibited the growth and metastasis of HCC cell lines in vitro and in vivo. Serum lncRNA-AF085935 was helpful to discriminate HCC from hepatitis B viral infected patients and healthy controls [
22]. Injection of the lncRNA PTENP1-expressing vectors into mice bearing HCC tumors effectively mitigated the tumor growth, suppressed intratumoral cell proliferation, elicited apoptosis, autophagy and inhibited angiogenesis [
23]. These findings suggested that lncRNAs might play important roles in HCC initiation and development and have a great potential for clinical application.
In the present study, we observed a high BANCR expression in HCC specimens and cell lines, providing the first evidence that BANCR overexpression was closely associated with HCC carcinogenesis. Then, we correlated increased BANCR levels with aggressive clinicopathological features of HCC tissues. Downregulation of BANCR in Hep3B cells would reduce cell proliferation, enhance cell apoptosis, and impair cell invasion and migration. These findings revealed that BANCR might be involved in HCC progression and contribute to molecular-targeted therapy. In addition, our research showed that HCC patients with high BANCR levels tended to have shorter overall survival than patients with lower levels. Multivariate Cox hazard regression analysis identified high BANCR expression as an independent indicator of unfavorable prognosis. To our knowledge, this is the first study to analyze the expression and clinical significance of BANCR in HCC.
BANCR has been reported as an oncogene in several types of human malignancies. BANCR levels in human malignant melanoma tissues increased with advanced tumor stages, and the knockdown of BANCR suppressed melanoma cell proliferation and migration through MAPK pathway [
13,
24]. BANCR overexpression correlated with tumor stage and lymph node metastasis in colorectal cancer and contributed to cancer cell migration through inducing epithelial-mesenchymal transition. In gastric cancer, BANCR expression was increased in tumor tissues compared with paired adjacent normal tissues. High BANCR levels were positively associated with clinical stage, tumor depth, lymph node and distant metastasis, and poor prognosis [
18]. In retinoblastoma, BANCR regulated cell proliferation, migration, and invasion in vitro and overexpressed BANCR expression linked with tumor size, choroidal invasion, and optic nerve invasion [
15].
In contrast to the tumor-promoting properties mentioned above, Sun et al. reported that BANCR was obviously downregulated in non-small cell lung cancer tissues and that reduced BANCR expression was associated with larger tumor size, lymph node metastasis, advanced TNM stage, and shorter overall survival. Ectopic expression of BANCR impaired cell viability and invasion, leading to the inhibition of metastasis in vitro and in vivo [
16]. Taken together, the role of lncRNA BANCR in human malignancies may be multifaceted and determined by the distinct context in various microenvironments.
EMT is one of the key processes for primary tumor cells to acquire a migratory capacity [
25]. Reduced E-cadherin expression and increased vimentin expression are associated with HCC progression [
26,
27]. Emerging evidence demonstrates that lncRNAs, including BANCR, may regulate EMT processes in several cancer types [
19,
28‐
30]. In the present study, BANCR downregulation resulted in upregulated E-cadherin and downregulated vimentin protein levels. These findings indicated that BANCR might be involved in the regulation of EMT in HCC, providing a possible explanation for BANCR-related high cell migration.
Competing interest
The authors declare that they have no competing interests.
Authors’ contributions
TZ and YG conceived, designed, and performed the experiments. TZ analyzed the data. YG contributed to the reagents, materials, and analysis tools. TZ and YG wrote the paper. Both authors read and approved the final manuscript.